Restaurant Chains and Food Companies Adjust as Ozempic Mania Sparks Portion Size Cuts

Restaurant chains are adapting to changing consumer behavior spurred by the popularity of GLP-1 drugs like Ozempic. Olive Garden and The Cheesecake Factory have reduced portion sizes in response to shifting dietary trends. The move reflects broader industry concerns about how weight-loss drug usage is reshaping eating habits.

GEN Restaurant Group reported Q3 2025 revenue of $50.4 million, a 2.7% increase year-over-year but below expectations. Same-store sales declined by 9.9%, and the company posted a net loss of $0.11 per share. Despite these results, the company remains optimistic about its full-year revenue goals and expansion plans.

Good Times Restaurants Inc. also faced a 10% revenue drop in Q1 2026, although it maintained stable earnings of $0.02 per share. CEO Ryan Zink announced plans to raise menu prices by 1.1% and expand the Bad Daddy's brand to counteract the impact of inflation and GLP-1 trends.

Why Did This Happen?

The rise in GLP-1 drug adoption has led to a notable shift in consumer appetite. Restaurant chains and food manufacturers are responding to a market where customers are consuming smaller portions or opting for more health-conscious choices. Olive Garden's decision to cut portions underscores the growing influence of weight-loss medications on dining habits.

GEN Restaurant Group is navigating challenges such as high meat costs and a slowing consumer appetite. The company's CEO downplayed same-store sales declines, emphasizing its expansion strategy and long-term growth potential. Despite these difficulties, it aims to expand its grocery store initiatives and maintain 2024 pricing levels.

How Did Markets React?

Pharmaron Beijing saw its shares surge over 8% following a $200 million investment commitment from Eli Lilly for a diabetes and weight-loss drug manufacturing partnership. The deal marks a significant milestone for the company and highlights its growing role in the global pharmaceutical supply chain.

David Protein, on the other hand, faces legal scrutiny over its protein bar nutritional labeling. A class-action lawsuit alleges the company's products contain significantly more calories and fat than stated. Independent testing reportedly showed discrepancies of up to 83% for calories and 400% for fat. The company has denied the allegations and pledged to defend itself vigorously.

Good Times Restaurants' stock closed at $1.23, down 4.07%, despite operational improvements in labor costs and menu innovations. The company's focus on debt reduction and cash preservation reflects its cautious approach in an uncertain market.

GEN Restaurant Group's shares rose 4.73% in after-hours trading to $2.88, despite a challenging quarter. Investors appear to be betting on the company's long-term strategy, including new grocery store initiatives that could add $100 million in revenue over the next four to five years.

What Are Analysts Watching Next?

Analysts are closely monitoring how restaurant chains adapt to the evolving health and wellness landscape. The success of menu price increases and brand expansion could determine future performance for companies like Good Times Restaurants and GEN Restaurant Group.

Pharmaron Beijing's partnership with Eli Lilly could set a precedent for future collaborations in the diabetes and weight-loss drug markets. The company's ability to scale its manufacturing capabilities and maintain quality control will be key factors for investors.

David Protein's legal battle will be a critical test for the brand's reputation and market position. If the lawsuit proceeds, it could lead to regulatory scrutiny and consumer backlash, affecting future sales and brand loyalty.

Overall, the food and restaurant sectors are navigating a period of significant change driven by health trends and consumer behavior shifts. Companies that can adapt their strategies to align with these changes may find new growth opportunities in a market that is evolving rapidly.